Viewing records where tag name contains "news" View All

EU Marketing Approval Granted for VivaGel® BV

Sep 24th, 2015

Starpharma today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.

Read More

Starpharma signs drug delivery license with AstraZeneca

Sep 7th, 2015

Starpharma today announced the signing of a licensing agreement with global pharmaceutical company AstraZeneca. The agreement enables the development and commercialisation by AstraZeneca of compounds directed at a defined family of targets using Starpharma’s DEP® drug delivery technology. The DEP® platform centres on use of Starpharma’s proprietary dendrimers, with the aim of enhancing the dosing and efficacy characteristics of pharmaceuticals.

Read More

M&G Substantial Shareholder Notice

Nov 24th, 2011

M&G has today lodged a substantial shareholder notice with the ASX advising a 6.7% shareholding in Starpharma following their investment of AUD$20 million in the Share Placement announced last week.

Read More

Starpharma to expand agricultural program through $250,000 funding

Mar 3rd, 2011

Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates. 

Read More